EP0572287A3 - Use of cyclic double-stranded oligonucleotides containing the binding site for a transcription factor for inhibiting gene expression - Google Patents

Use of cyclic double-stranded oligonucleotides containing the binding site for a transcription factor for inhibiting gene expression Download PDF

Info

Publication number
EP0572287A3
EP0572287A3 EP19930400154 EP93400154A EP0572287A3 EP 0572287 A3 EP0572287 A3 EP 0572287A3 EP 19930400154 EP19930400154 EP 19930400154 EP 93400154 A EP93400154 A EP 93400154A EP 0572287 A3 EP0572287 A3 EP 0572287A3
Authority
EP
European Patent Office
Prior art keywords
transcription factor
binding site
gene expression
oligonucleotides containing
stranded oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19930400154
Other languages
German (de)
French (fr)
Other versions
EP0572287A2 (en
Inventor
Marta Blumenfeld
Catherine Clusel
Nathalie Enjolras
Edgarto Ugarte Romero
Marc Vasseur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Biodevelopment SAS
Original Assignee
Genset SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset SA filed Critical Genset SA
Priority to JP5288598A priority Critical patent/JPH08107787A/en
Publication of EP0572287A2 publication Critical patent/EP0572287A2/en
Publication of EP0572287A3 publication Critical patent/EP0572287A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention concerns the use of a double-stranded closed oligonucleotide containing a binding site for a given transcription factor, e.g. HNF-1 factor, for inhibiting the expression of a given gene under the control of said transcription factor, e.g. liver-specific genes coding for fibrinogen, transthyretin, apolipoprotein B or the pre-S₁ gene of hepatitis B virus.
Particularly preferred oligonucleotides are the ones containing the sequence 5'GTTANT3', wherein N can be any of A,T,C or G.
EP19930400154 1991-04-25 1993-01-22 Use of cyclic double-stranded oligonucleotides containing the binding site for a transcription factor for inhibiting gene expression Withdrawn EP0572287A3 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP5288598A JPH08107787A (en) 1993-01-22 1993-10-25 Inhibition of gene of pathologic subject expressed by double-strand cyclic oligonucleotide containing dna bonding region for transcription factor under control of said factor

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9105114A FR2675803B1 (en) 1991-04-25 1991-04-25 CLOSED, ANTISENSE AND SENSE OLIGONUCLEOTIDES AND THEIR APPLICATIONS.
PCT/FR1992/000370 WO1992019732A1 (en) 1991-04-25 1992-04-24 Closed sense and antisense oligonucleotides and uses thereof
WOPCT/FR92/00370 1992-04-24

Publications (2)

Publication Number Publication Date
EP0572287A2 EP0572287A2 (en) 1993-12-01
EP0572287A3 true EP0572287A3 (en) 1994-01-12

Family

ID=9412249

Family Applications (2)

Application Number Title Priority Date Filing Date
EP92910423A Expired - Lifetime EP0581848B1 (en) 1991-04-25 1992-04-24 Closed sense and antisense oligonucleotides and uses thereof
EP19930400154 Withdrawn EP0572287A3 (en) 1991-04-25 1993-01-22 Use of cyclic double-stranded oligonucleotides containing the binding site for a transcription factor for inhibiting gene expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP92910423A Expired - Lifetime EP0581848B1 (en) 1991-04-25 1992-04-24 Closed sense and antisense oligonucleotides and uses thereof

Country Status (11)

Country Link
US (1) US6369038B1 (en)
EP (2) EP0581848B1 (en)
JP (1) JPH06506834A (en)
AT (1) ATE244303T1 (en)
AU (1) AU660679B2 (en)
CA (1) CA2102229A1 (en)
DE (1) DE69233117T2 (en)
DK (1) DK0581848T3 (en)
ES (1) ES2199936T3 (en)
FR (1) FR2675803B1 (en)
WO (1) WO1992019732A1 (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683874A (en) * 1991-03-27 1997-11-04 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
EP0580754A1 (en) * 1991-04-18 1994-02-02 The Salk Institute For Biological Studies Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
FR2675803B1 (en) * 1991-04-25 1996-09-06 Genset Sa CLOSED, ANTISENSE AND SENSE OLIGONUCLEOTIDES AND THEIR APPLICATIONS.
US5698391A (en) * 1991-08-23 1997-12-16 Isis Pharmaceuticals, Inc. Methods for synthetic unrandomization of oligomer fragments
AU683011B2 (en) * 1992-01-13 1997-10-30 Duke University Enzymatic RNA molecules
US6521601B1 (en) * 1992-04-14 2003-02-18 Signal Pharmaceuticals, Inc. Method and composition for inhibition of viral replication
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
FR2703053B1 (en) * 1993-03-26 1995-06-16 Genset Sa STAPLE AND SEMI-STAPLE OLIGONUCLEOTIDES, PREPARATION METHOD AND APPLICATIONS.
FR2707880B1 (en) * 1993-06-30 1995-10-06 Rhone Poulenc Rorer Sa Pharmaceutical compositions and their use, in particular for the treatment of neurodegenerative diseases.
FR2708270B1 (en) * 1993-07-28 1995-10-20 Genset Sa Antisense oligonucleotides directed against Herpes Simplex virus types 1 & 2.
AU7518194A (en) 1993-07-29 1995-02-28 Regents Of The University Of California, The Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof
US5859226A (en) * 1993-07-29 1999-01-12 Regents Of The University Of California, The Polynucleotide decoys that inhibit MHC-II expression and uses thereof
FR2710846B1 (en) * 1993-10-04 1995-12-22 Rhone Poulenc Rorer Sa Pharmaceutical compositions and their use, in particular in the treatment of neurogenerative diseases.
US8431119B2 (en) 1993-10-04 2013-04-30 Aventis Pharma S.A. Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
EP0736093B1 (en) * 1993-12-23 2003-03-19 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL
FR2714383B1 (en) * 1993-12-29 1996-02-09 Centre Nat Rech Scient Control of gene expression.
WO1995024222A1 (en) * 1994-03-07 1995-09-14 University Of Medicine & Dentistry Of New Jersey Cyclic polycationic polymer-oligonucleotide conjugates and methods for preparing same
US5674683A (en) * 1995-03-21 1997-10-07 Research Corporation Technologies, Inc. Stem-loop and circular oligonucleotides and method of using
FR2732344B1 (en) * 1995-04-03 1997-06-20 Genset Sa OLIGONUCLEOTIDES WITH CROSS-COALENT BINDING, PREPARATION METHOD AND SYNTHON USEFUL IN THE PROCESS
FR2732971B1 (en) * 1995-04-13 1997-07-04 Genset Sa OLIGONUCLEOTIDE SENSE INHIBITOR OF HERPES SIMPLEX VIRUS (HSV) WITH HALTERED STRUCTURE
US6509149B2 (en) * 1995-06-06 2003-01-21 Hybridon, Inc. HPV-specific oligonucleotides
ES2109177B1 (en) * 1995-10-11 1998-07-16 Univ Barcelona GENERAL PROCEDURE FOR THE PREPARATION OF CYCLIC AND INTERMEDIATE OLIGONUCLEOTIDES FOR THE SAME.
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
WO1997047639A1 (en) * 1996-06-10 1997-12-18 Laboratory Of Molecular Biophotonics Photocleavable cyclic oligonucleotide
DE19631919C2 (en) * 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-sense RNA with secondary structure
EP0860167A1 (en) * 1997-01-30 1998-08-26 Robert Gurny RNA-and DNA- based active agents in nanoparticles
CA2311572A1 (en) 1997-12-17 1999-06-24 Genset S.A. Extended cdnas for secreted proteins
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CZ295108B6 (en) 1998-03-20 2005-05-18 Benitec Australia Ltd Synthetic gene comprising dispersed or foreign deoxyribonucleic molecule and a gene construct containing such a synthetic gene
EP1115859A2 (en) * 1998-09-21 2001-07-18 Ribozyme Pharmaceuticals, Inc. Hairpin hybridizer molecules for modulation of gene expression
EP2314700A1 (en) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA
DE19956568A1 (en) * 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
AU2008202208C1 (en) * 1999-01-30 2014-04-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
IL145778A0 (en) * 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
DE19935756A1 (en) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Covalently closed nucleic acid molecule for immune stimulation
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
DE10100586C1 (en) 2001-01-09 2002-04-11 Ribopharma Ag Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1191097A1 (en) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
ES2215494T5 (en) 2000-12-01 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Small RNA molecules that mediate RNA interference
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US20020132257A1 (en) * 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
CA2452260C (en) 2001-07-24 2011-09-06 Genset S.A. Novel variants and exons of the glyt1 transporter
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
CA2462139A1 (en) * 2001-09-27 2003-04-03 Timothy Albert Holton Stem-loop vector system
CN1240439C (en) * 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 Genetic switch medicine for treating tumor
PT1527176E (en) 2002-08-05 2007-04-30 Atugen Ag Further novel forms of interfering rna molecules
WO2004083432A1 (en) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EP1644531A4 (en) * 2003-06-25 2009-03-11 Somagenics Inc Polynucleotides capable of target-dependent circularization and topological linkage
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
CN1860228B (en) * 2003-09-30 2010-04-28 安琪士摩奇株式会社 Staple type oligonucleotide and drug comprising the same
KR100698056B1 (en) * 2003-12-26 2007-03-23 엘지.필립스 엘시디 주식회사 Laser Beam Pattern Mask and the Method for Crystallization with the Same
CN101031569B (en) 2004-05-13 2011-06-22 艾科斯有限公司 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
JP2008500338A (en) * 2004-05-25 2008-01-10 イコス・コーポレイション Method for treating and / or preventing abnormal proliferation of hematopoietic cells
WO2005116223A1 (en) * 2004-05-28 2005-12-08 Mologen Ag Method for the production of suitable dna constructs for specific inhibition of gene expression by rna interference
CN101107362A (en) 2004-10-21 2008-01-16 文甘扎公司 Methods and materials for conferring resistance to pests and pathogens of plants
US20080287469A1 (en) * 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
DE202005004135U1 (en) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Multi-component packaging with applicator
JP2008538500A (en) * 2005-04-22 2008-10-30 アカデミス ツィーケンホイス ライデン Regulation of exon recognition in pre-mRNA by interference with SR protein binding and RNA secondary structure
EP1986697B1 (en) * 2006-02-17 2016-06-29 GE Healthcare Dharmacon, Inc. Compositions and methods for inhibiting gene silencing by rna interference
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
CA2660523C (en) 2006-08-11 2019-03-19 Prosensa Technologies B.V. Methods and means for treating dna repeat instability associated genetic disorders
ES2619314T3 (en) 2007-05-11 2017-06-26 Adynxx, Inc. Gene Expression and Pain
EP2167135A2 (en) * 2007-07-12 2010-03-31 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
CA2693048C (en) * 2007-07-12 2016-10-18 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
HUE028662T2 (en) 2007-10-26 2016-12-28 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
WO2009099326A1 (en) * 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
US8236499B2 (en) 2008-03-28 2012-08-07 Pacific Biosciences Of California, Inc. Methods and compositions for nucleic acid sample preparation
US8628940B2 (en) 2008-09-24 2014-01-14 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
EP3170904B1 (en) 2008-03-28 2017-08-16 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid sequencing
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8383369B2 (en) * 2008-09-24 2013-02-26 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
WO2010036287A1 (en) 2008-09-24 2010-04-01 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
AU2009313878B2 (en) 2008-11-13 2016-01-07 Gilead Calistoga Llc Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
BRPI1012333A2 (en) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisomers of 2-purinyl-3-tolyl-quinazolinones derivatives and methods of use
US20100257634A1 (en) * 2009-04-03 2010-10-07 Venganza Inc. Bioassay for gene silencing constructs
US8546409B2 (en) * 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
WO2010123369A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
CN102647987A (en) 2009-07-21 2012-08-22 吉里德卡利斯托加公司 Treatment of liver disorders with PI3K inhibitors
WO2011078672A1 (en) 2009-12-24 2011-06-30 Prosensa Technologies B.V. Molecule for treating an inflammatory disorder
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
CA2862628C (en) 2012-01-27 2021-08-24 Prosensa Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
WO2013130868A1 (en) * 2012-02-29 2013-09-06 Isis Pharmaceuticals, Inc. Methods for modulating fibrinogen expression
BR112014021935A2 (en) 2012-03-05 2019-09-24 Gilead Calistoga Llc polymorphic forms of (s) -2- (1- (9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazoline-4 (3h) one
JP6251247B2 (en) 2012-05-10 2017-12-20 エーダイニクス インコーポレイテッド Formulation for active ingredient delivery
NZ720867A (en) 2013-12-20 2018-01-26 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
BR112016028642A2 (en) 2014-06-13 2017-08-22 Gilead Sciences Inc compound, pharmaceutical composition, method of treating a disease or condition, method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide, method of inhibiting immune reactions or overgrowth or destructive cancer cell proliferation, kit, and, use of a compound, salt, isomer or a pharmaceutically acceptable mixture thereof.
JP6705807B2 (en) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド Oligonucleotide decoys for treating pain
CN112639110A (en) 2018-06-22 2021-04-09 阿斯克肋匹奥生物制药公司 Vectors for gene delivery to persist in cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017484A1 (en) * 1991-03-27 1992-10-15 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides
WO1992019732A1 (en) * 1991-04-25 1992-11-12 Genset Closed sense and antisense oligonucleotides and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2115A1 (en) * 1987-12-15 1991-07-05 Gene Shears Pty Ltd RIBOZYNES
US5436141A (en) * 1989-02-24 1995-07-25 University Of Medicine And Dentistry Of New Jersey Method for synthesizing stable single-stranded CDNA in eukaryotes by means of a bacterial retron and products
US5434070A (en) * 1989-02-24 1995-07-18 The University Of Medicine And Dentistry Of New Jersey Reverse transcriptases from Escherichia coli and Myxococcus xanthus
US5405775A (en) * 1989-02-24 1995-04-11 The University Of Medicine And Dentistry Of New Jersey Retrons coding for hybrid DNA/RNA molecules
DE3928900A1 (en) * 1989-08-31 1991-03-07 Europ Lab Molekularbiolog New psoralen-modified nucleotide derivatives - used as anti-sense nucleotide(s) in the treatment of viral infections, e.g. AIDS
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
EP0580754A1 (en) 1991-04-18 1994-02-02 The Salk Institute For Biological Studies Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017484A1 (en) * 1991-03-27 1992-10-15 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides
WO1992019732A1 (en) * 1991-04-25 1992-11-12 Genset Closed sense and antisense oligonucleotides and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOESSAYS vol. 14, no. 9, September 1992, pages 579 - 587 TRONCHE, F. ET AL 'HNF-1, A HOMEOPROTEIN MEMBER OF THE HEPATIC TRANSCRIPTION REGULATORY NETWORK' *
GENES AND DEVELOPMENT vol. 2, no. 8, August 1988, pages 957 - 974 CEREGHINI, SILVIA ET AL 'A LIVER SPECIFIC FACTOR ESSENTIAL FOR ALBUMIN TRANSCRIPTION DIFFERS BETWEEN DIFFERENTIATED AND DEDIFFERENTIATED RAT HEPATOMA CELLS' *
MOLECULAR AND CELLULAR BIOLOGY vol. 9, no. 11, November 1989, pages 4759 - 4766 TRONCHE, F. ET AL 'THE RAT ALBUMIN PROMOTER: COOPERATION WITH UPSTREAM ELEMENTS IS REQUIRED WHEN BINDING OF APF/HNF1 TO THE PROXIMAL ELEMENT IS PARTIALLY IMPAIRED BY MUTATION OR BACTERIAL METHYLATION' *

Also Published As

Publication number Publication date
DK0581848T3 (en) 2003-10-27
DE69233117D1 (en) 2003-08-07
EP0581848A1 (en) 1994-02-09
ES2199936T3 (en) 2004-03-01
AU660679B2 (en) 1995-07-06
EP0581848B1 (en) 2003-07-02
EP0572287A2 (en) 1993-12-01
AU1759692A (en) 1992-12-21
WO1992019732A1 (en) 1992-11-12
US6369038B1 (en) 2002-04-09
ATE244303T1 (en) 2003-07-15
FR2675803A1 (en) 1992-10-30
CA2102229A1 (en) 1992-10-26
DE69233117T2 (en) 2004-04-15
JPH06506834A (en) 1994-08-04
FR2675803B1 (en) 1996-09-06

Similar Documents

Publication Publication Date Title
EP0572287A3 (en) Use of cyclic double-stranded oligonucleotides containing the binding site for a transcription factor for inhibiting gene expression
ATE239090T1 (en) METHOD FOR GENERATING SINGLE STRANDED DNA MOLECULES
PL298239A1 (en) Genetic sequences encoding the enzymes of flavonoid path and their applications
EP1156108A3 (en) Use of exo-sample nucleotides in gene cloning
AU7947591A (en) Oligonucleotide analogs with terminal 3'-3' or 5'-5' internucleotide linkages
IL101397A (en) Single-stranded circular oligonucleotides capable of binding to a target dna or rna methods for the use thereof and pharmaceutical compositions containing them
WO1994005791A3 (en) Dorsal tissue affecting factor and compositions
DK0491878T3 (en) Preparations for Inhibition of Protein Hormone Formation and Uses thereof
DE69121975T2 (en) Specific detection of Mycobacterium tuberculosis
EP0775745A3 (en) Cathepsin G-inhibiting aptamers
AU6144294A (en) Plant virus resistance conferring polyribozyme and resistant plants producing same
SE9502259D0 (en) Oligonucleotides to inhibit the expression of isoprenyl protein transferases
AU6888094A (en) Nucleic acid sequence and plasmids comprising at least one phage resistance mechanism, bacteria in which they are present, and their use
ATE209683T1 (en) PLANT RESISTANT TO AT LEAST TWO VIRUSES AND ITS PREPARATION
IL153833A0 (en) Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches
WO1999060140A3 (en) Geminivirus inducible promoter sequences and the uses thereof
ITRM920438A1 (en) NUCLEOTIDIC CODING SEQUENCES FOR A POLYMERASE DNA.
DK51690A (en) SPECIFIC, MOLECULAR DNA PROBLEMS FOR MASCULINES OF THE BOS TYPE
ATE212057T1 (en) RIBOZYM STRUCTURE DERIVED FROM THE GENOMIC RNA OF THE HEPATITIS DELTA VIRUS
WO2000009689A3 (en) A single gene encoding aortic-specific and striated-specific muscle cell isoforms, its regulatory sequences and uses thereof
WO1999029844A3 (en) Novel retroelements zam and idemfix, and their integrase
FI902353A (en) BIOLOGICAL COMPOSITION AVERAGE FOR THE PURPOSE OF A GENE TILLSAETNING AV HORMONALISKA LAEKEMEDEL I FOER VARJE DJUR SAEREGEN BETESTYP.
TH28996B (en) Specific oligonucleotides for hepatitis C virus
FR2721617B1 (en) Nucleic acid fragments, derived from the genome of Mycobacterium xenopi and their applications.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RTI1 Title (correction)
AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19940524

17Q First examination report despatched

Effective date: 19980507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000301